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Available online 12 March 2010Background: Associations between depression, and possibly anxiety, with cardiovascular disease
have been established in the general population and among heart patients. This study examined
whether cardiovascular disease was more prevalent among a large cohort of depressed and/or
anxious persons. In addition, the role of speciﬁc clinical characteristics of depressive and anxiety
disorders in the association with cardiovascular disease was explored.
Methods: Baseline data from the Netherlands Study of Depression and Anxiety were used,
including personswith a current (i.e. past year) or remittedDSM-IVdepressiveor anxiety disorder
(N=2315) and healthy controls (N=492). Additional clinical characteristics (subtype, duration,
severity, and psychoactive medication) were assessed. Cardiovascular disease (stroke and
coronary heart disease) was assessed using algorithms based on self-report and medication use.
Results: Personswith current anxiety disorders showed an about three-fold increasedprevalence of
coronary heart disease (OR anxiety only=2.70, 95%CI=1.31–5.56; OR comorbid anxiety/
depression=3.54, 95%CI=1.79–6.98). No associations were found for persons with depressive
disorders only or remitted disorders, nor for stroke. Severity of depressive and anxiety symptoms—
but noother clinical characteristics—most strongly indicated increasedprevalenceof coronaryheart
disease.
Limitations: Cross-sectional design.
Conclusions: Within this large psychopathology-based cohort study, prevalence of coronary heart
disease was especially increased among persons with anxiety disorders. Increased prevalence of
coronary heart disease among depressed personswas largely owing to comorbid anxiety. Anxiety—
alone as well as comorbid to depressive disorders—as risk indicator of coronary heart disease
deserves more attention in both research and clinical practice.




In 1993 Frasure-Smith et al. showed that after amyocardial
infarction, depressed personswere four-to-ﬁve times as likely
to die within the next six months than their non-depressedHL Amsterdam, The
5664.
ngs@ggzingeest.nl
All rights reserved.counterparts. Although this initial observation turned out to
overestimate the true relationship between depression and
heart disease (e.g. Nicholson et al., 2006), since then, many
studies have examined their association. Both depression and
heart disease are leading disorders when considering disease
burden. The World Health Organization projected depression
and heart disease to becomenumbers 1 and 2, respectively, on
the list of diseases with the greatest loss of ‘disability adjusted
life years’ in 2030 in high-income countries and numbers 2
and3worldwide (Mathers and Loncar, 2006). This suggests an
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when depression, heart disease and especially their comor-
bidity could be prevented through increasing knowledge on
the link between these two disabling diseases.
Research thus far has mainly focused on two kinds of
populations: heart disease patients and the general population.
Meta-analyses have shown that among heart patients depres-
sion is associated with an 1.8 to 2.6 increased risk of a
subsequent cardiovascular event or death (Barth et al., 2004;
Nicholsonet al., 2006;vanMelle et al., 2004),while in thegeneral
population depression increases risk of cardiovascular disease
(CVD) about 1.6 to 1.8 times (Nicholson et al., 2006;Rugulies,
2002;Van der Kooy et al., 2007;Wulsin and Singal, 2003).
Although, as suggested by Nicholson et al. (2006), these
estimates may still be inﬂated due to incomplete and biased
reporting of adjustment for conventional risk factors and CVD
severity. Studies on prevalence of CVD within a psychopathol-
ogy-based population are largely lacking. From a psychiatrist
perspective, it would be of great importance to know whether
clinically depressed patients indeed have a higher prevalence of
CVD and howmuch increased exactly this prevalence is. What's
more, it has hardly been addressed whether speciﬁc character-
istics of depression, such as age of onset, duration, or severity of
the disorder could further determine the exact CVD probability,
orwhether the association is restricted to speciﬁc subtypes, such
as atypical or melancholic depression. This knowledge could
give insight into underlying mechanisms that relate depression
and CVD as well as into which patients should be most closely
monitored for cardiovascular dysfunctioning.
Besides depression, some studies have suggested anxiety to
be associated with CVD as well (Albert et al., 2005;Fan et al.,
2008;Kawachi et al., 1994). Anxiety disorders lead to compara-
ble levels of disability as depression and heart disease (Buist-
Bouwman et al., 2006) and have been found to increase risk of
premature all-cause and cardiovascular death (Denollet et al.,
2009;Phillips et al., 2009). The association between anxiety and
CVD, however, has been far less studied than the link between
depression and heart disease. Even less studied has been the
association between anxiety characteristics (subtype, duration,
and severity) and CVD. Furthermore, as depression and anxiety
are often found to be comorbid, it would be of great importance
to study the association between depression and anxiety with
CVD in concert. This could shed light on the speciﬁcity of
associations betweendepressive andanxiety disorders andCVD.
Therefore, in the present study within a large cohort of
depressed and/or anxious persons and healthy controls we
examined the (extent of the) association between the
presence of a psychiatric diagnosis of depressive and/or
anxiety disorder with CVD. In addition, we assessed the
speciﬁcity of these associations by directly comparing
depressive with anxiety disorders and by examining whether
speciﬁc characteristics of depressive and/or anxiety disorders
(subtype, duration, severity, and psychoactive medication)
could be identiﬁed that indicate increased probability of CVD.
2. Methods
2.1. Sample
The Netherlands Study of Depression and Anxiety (NESDA)
is an ongoing cohort study designed to investigate the long-term course and consequences of depressive and anxiety
disorders. Participants were 18 to 65 years old at baseline
assessment in 2004–2007 and were recruited from the
community (19%), general practice (54%) and secondary
mental health care (27%). A total of 2981 persons were
included, consisting of persons with a current or past
depressive and/or anxiety disorder (N=2329) and healthy
controls (N=652). A detailed description of the NESDA study
design and sampling procedures can be found elsewhere
(Penninx et al., 2008). The research protocol was approved by
the Ethical Committee of participating universities and after
complete description of the study all respondents provided
written informed consent.
As subclinical symptoms of on the one hand depressive
and anxiety disorders and on the other hand CVD could to a
certain degree resemble each other (e.g. feeling tired or pain
on the chest) and could therefore falsely indicate or elevate
an association between them, persons with subthreshold
symptoms of depression or anxiety but no formal diagnosis of
depressive or anxiety disorder (N=158) and persons who
self-reported CVD without reporting accompanying appro-
priate medication use (N=16) were excluded (see below for
more details), leaving 2807 persons for the present analyses.
2.2. Psychopathology and clinical characteristics
Presence of depressive disorder (major depressive disor-
der and dysthymia) and anxiety disorder (social phobia,
generalized anxiety disorder, panic disorder and agorapho-
bia) was established using the Composite Interview Diagnos-
tic Instrument (CIDI) according to DSM-IV criteria (American
Psychiatric Association, 2001). The CIDI is a highly reliable
and valid instrument for assessing depressive and anxiety
disorders (Wittchen, 1994) and was administered by spe-
cially trained research staff. Based on CIDI, participants were
categorized as having no, current (i.e. in past year), or a
remitted (lifetime, but not current) depressive and/or anxiety
disorder. In addition, a categorical variable was constructed
classifying persons as having no depressive or anxiety
disorder, remitted depressive or anxiety disorder, current
depressive disorder only, current anxiety disorder only, or
current depressive and anxiety disorder.
Clinical characteristics examined included the subtype,
duration and severity of the depressive or anxiety disorder.
Next to CIDI diagnoses, subtypes of depressive disorder
included ﬁrst onset versus recurrent major depressive
disorder (based on CIDI interview), presence of an atypical
symptom proﬁle, and presence of a melancholic symptom
proﬁle. Atypical symptom proﬁle (mood reactivity and ≥2 of
hyperphagia, hypersomnia, leaden paralysis, and interper-
sonal rejection sensitivity) was constructed by comparison of
items of the 28-item self-report Inventory of Depressive
Symptoms (IDS (Rush et al., 1996)) with DSM-IV criteria for
atypical depression following Novick's algorithm (Novick et
al., 2005). Similarly, melancholic symptom proﬁle (lack of
mood reactivity or loss of pleasure and ≥3 of distinct mood
quality, mood worse in morning, early morning awakening,
psychomotor retardation or agitation, anorexia/weight loss,
and guilt feelings) was constructed based on comparison of
IDS items with DSM-IV criteria using the algorithm proposed
by Khan (Khan et al., 2006). Additionally, for both depressive
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onset (≥30 years old) and early onset (b30 years old) of the
psychiatric disorder, as derived from the CIDI interview.
Using the Life Chart method (Lyketsos et al., 1994), a detailed
account of the presence of depressive and anxiety symptoms
during the past four to ﬁve years was assessed among persons
with depressive or anxiety disorders. From this, the percent of
time patients reported depressive or anxiety symptoms was
computed as a measure of duration. Severity of depressive
symptoms was assessed by means of the IDS; severity of
anxiety symptoms by means of the 21-item Beck Anxiety
Inventory (BAI (Beck et al., 1988)).
To account for possible psychoactive medication effects,
medication use was assessed based on drug container inspec-
tion of all drugs used in the pastmonth and classiﬁed according
to the World Health Organization Anatomical Therapeutic
Chemical (ATC) classiﬁcation (WHO Collaborating Centre for
Drug Statistics Methodology, 2007). As effects of psychoactive
medication are likely negligible when used infrequently, use of
psychoactive medication was only considered present when
taken on a regular basis (at least 50% of the time). Antidepres-
sants included selective serotonin reuptake inhibitors (ATC-
code N06AB), tricyclic antidepressants (N06AA) and other
antidepressants (N06AF/N06AX). Benzodiazepines included
ATC-codes N03AE, N05BA, N05CD and N05CF.
2.3. Cardiovascular disease
Cardiovascular disease (CVD) included stroke, angina
pectoris, myocardial infarction, percutaneous transluminal
coronary angioplasty and coronary artery bypass grafting and
was adjudicated using standardized algorithms considering
self-report and medication use (based on drug container
inspection and ATC coding). During the interview, partici-
pants were asked if they ever had a stroke, a heart condition
or a heart attack, and to specify the kind of condition. In
addition, it was askedwhether subjects were ever troubled by
chest pain during physical strain and whether the pain
disappeared within 10 min after standing still or taking a
tablet under the tongue. If subjects responded positively on
both questions this was regarded as an indication of angina
pectoris (symptoms). Stroke was identiﬁed by self-report
supported by use of either anticoagulant/antiplatelet agents
(antithrombotic agents [ATC-code B01], acetylsalicylic acid
[N02BA01; ≥50% use of ≤100 mg], or carbasalate calcium
[N02BA15]), any medication for hypertension (antihyperten-
sives [C02], diuretics [C03], beta blocking agents [C07],
calcium channel blockers [C08], agents acting on renin–
angiotensin system [C09]), or lipid modifying agents (C10).
Angina pectoris and myocardial infarction were only consid-
ered present when self-report (or symptoms) of the disease
was supported by use of medication for coronary heart
disease (CHD; beta blocking agents [C07], nitrate vasodilators
[C01DA], calcium channel blockers [C08], or anticoagulant/
antiplatelet agents [B01, N02BA01 ≥50% use of ≤100 mg,
N02BA15]). When self-report was not conﬁrmed by medica-
tion use, CVD was considered to be ‘undetermined’ and
subjects were excluded from the analyses (N=16). When
angina symptoms (N=510) were not supported by medica-
tion use, persons were considered as having no CVD
(N=413). Percutaneous transluminal coronary angioplastyand coronary artery bypass grafting were based on self-report
only. CVD was subdivided into stroke and CHD (angina
pectoris, myocardial infarction, angioplasty or bypass). For
sensitivity analyses, as beta blockers are sometimes pre-
scribed for anxiety symptoms, a secondary measure of CHD
excluded persons with symptoms of angina pectoris and use
of a beta blocker only (N excluded=32).
2.4. Covariates
Sociodemographic characteristics included age, sex, and
years of education. As lifestyle characteristics can be associated
with both CVD and depression/anxiety, smoking status (never,
former, current), alcohol intake (b1, 1–14, N14 drinks per
week), physical activity (measured with the International
Physical Activity Questionnaire (Craig et al., 2003) in MET-
minutes [ratio of energy expenditure during activity compared
to rest times the number of minutes performing the activity]
per week) and body mass index (BMI; weight in kilograms
divided by height in meters squared) were assessed.
2.5. Statistical analyses
Sample characteristics were compared across persons
with and without CVD using independent t-tests for contin-
uous variables and chi-square statistics for dichotomous and
categorical variables. Logistic regression analyses assessed
the associationwith CVD for depressive and anxiety disorders
separately and simultaneously, before and after adjustment
for a priori selected covariates (sociodemographic [age, sex,
years of education] and lifestyle [smoking status, alcohol
intake, physical activity, BMI]). Next, consistency of associa-
tions with regard to CVD were assessed by conducting
separate adjusted logistic regression analyses for subtypes
of CVD (stroke and CHD) and subtypes of CHD (angina
pectoris, myocardial infarction, and CHD surgery [angioplasty
or bypass]).
Speciﬁcity of associations with regard to clinical aspects of
the depressive or anxiety disorder was assessed in a sub-
sample of persons with current depressive and/or anxiety
disorders using sociodemographic-adjusted logistic regres-
sion analyses. First, the association with CVD of depressive
disorder versus anxiety disorder was directly compared.
Second, associations between speciﬁc depressive disorder or
anxiety disorder characteristics (subtype, duration, severity,
and psychoactive medication use) and CVD were examined.
3. Results
Mean age of the present samplewas 41.8 (SD=13.0) years,
66.4% were women, 19.4% had a remitted and 63.1% had a
current depressive or anxiety disorder, while 5.6% had CVD.
Table 1 describes sample characteristics comparing persons
with and without CVD. Persons with CVD were older, more
oftenmen, less educated, more often former smoker, less often
moderate drinker, and had a higher BMI. Also, persons with
CVD more often had a current anxiety disorder, but not
depressive disorder.
Table 2 describes the results of unadjusted and adjusted
logistic regression analyses assessing the association of depres-
sive and anxiety disorders with CVD. Remitted disorders were
Table 1







Age, years, mean (SD) 41.1 (12.9) 54.1 (7.8) b.001
Women, % 67.7 45.5 b.001
Years of education, mean (SD) 12.2 (3.3) 11.0 (3.2) b.001
Lifestyle variables
Smoking status .001
Never, % 28.4 18.6
Former, % 32.3 46.2
Current, % 39.3 35.3
Alcohol intake .05
b1 drink a week, % 32.2 37.8
1–14 drinks a week, % 52.1 42.3
N14 drinks a week, % 15.7 19.9
Physical activity






Body mass index, mean (SD) 25.4 (5.0) 28.6 (4.8) b.001
Depression and anxiety variables
Depressive disorder .14
No depressive disorder, % 30.6 23.7
Remitted depressive disorder, % 24.4 29.5




No anxiety disorder, % 37.9 26.3
Remitted anxiety disorder, % 14.6 14.1
Current (in past year)
anxiety disorder, %
47.5 59.6
Depressive and/or anxiety disorder .03




Current depressive disorder only 15.2 9.0




a Based on independent t-test for continuous variables and chi-square
statistics for dichotomous and categorical variables.
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adjustment current depressive and current anxiety disorders
were (OR=1.59, 95%CI=1.02–2.47; OR=2.18, 95%CI=1.45–
3.28, respectively). When the presence or absence of a
depressive or anxiety disorderwas combined in one categoricalTable 2




No depressive disorder 847
Remitted depressive disorder 693 1.56
Current (in past year) depressive disorder 1267 1.34
Anxiety disorder
No anxiety disorder 1046
Remitted anxiety disorder 408 1.40
Current (in past year) anxiety disorder 1353 1.81
Depressive and/or anxiety disorder
No depressive or anxiety disorder 492
Remitted depressive or anxiety disorder 544 1.45
Current depressive disorder only 418 0.86
Current anxiety disorder only 504 1.80
Current depressive and anxiety disorder 849 1.86
a Based on logistic regression analyses unadjusted and adjusted for age, sex, yeavariable, odds of CVDwere increased for personswith a current
anxiety disorder alone (OR=1.96, 95%CI=1.06–3.64) as well
as for those with a combined current anxiety and depressive
disorder (OR=2.35, 95%CI=1.33–4.20) compared to healthy
controls. Increased likelihood of CVD was not observed for
persons with a current depressive disorder only (OR=0.93,
95%CI=0.44–1.96).
Next, effects of depression/anxiety status were assessed
separately for odds of having stroke and odds of having CHD
(Table 3). Depressive and anxiety disorderswerenot associated
with stroke. In contrast, personswith a current anxiety disorder
were 2.5 to 3.5 times more likely to have CHD (OR anxiety
only=2.70, 95%CI=1.31–5.56; OR anxiety and depres-
sion=3.54, 95%CI=1.79–6.98). No signiﬁcant association
was found for persons with a depressive disorder only
(OR=1.41, 95%CI=0.61–3.23). To gain some insight into the
direction of the association between psychopathology and
CHD, we repeated the current analysis among persons with an
early onset (≤30 years) of depressive or anxiety disorder (N
excluded=269). Since CHD hardly occurs before the age of 30,
an early onset suggests that psychopathology was present
before CHD.Withinpersonswith anearly onset of depressiveor
anxiety disorder similar results were found (OR depression
only=1.37, 95%CI=0.59–3.20; OR anxiety only=2.37, 95%
CI=1.12–5.03; OR anxiety and depression=3.26, 95%
CI=1.59–6.68; data not tabulated). An additional analysis
excluded persons (N=32) who ‘earned’ their status of CHD
only based on angina symptoms and use of a beta blocker—
sometime used to relieve anxiety symptoms—, but substantial
associations remained (OR anxiety only=2.06, 95%CI=0.96–
4.44; OR anxiety and depression=2.89, 95%CI=1.41–5.93;
data not tabulated). When examining CHD subtypes (angina
pectoris, myocardial infarction, and CHD surgery) associations
for current anxiety disorder (with or without depressive
disorder)were found for all (see Table 3). Depressive disorders
alone also showed increased odds of especially angina pectoris
and myocardial infarction, but these were not statistically
signiﬁcant. Because associations of psychopathology were only
found with CHD and not stroke, all following analyses were
conducted with CHD as the outcome.
Fig. 1 shows that within persons with current psychopa-
thology (N=1770), persons with a current anxiety disorderAdjusted
95% CI p OR 95% CI p
REF REF
1.00–2.43 .05 1.50 0.93–2.40 .10
0.89–2.01 .16 1.59 1.02–2.47 .04
REF REF
0.82–2.38 .22 1.31 0.74–2.30 .35
1.24–2.64 .002 2.18 1.45–3.28 b.001
REF REF
0.81–2.62 .21 1.27 0.68–2.37 .45
0.43–1.74 .68 0.93 0.44–1.96 .85
1.01–3.20 .05 1.96 1.06–3.64 .03
1.10–3.16 .02 2.35 1.33–4.20 .004
rs of education, smoking status, alcohol use, physical activity and BMI.
Table 3
Association a of depressive and anxiety disorders with cardiovascular disease subtypes.











OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
No depressive or anxiety disorder REF REF REF REF REF
Remitted depressive or
anxiety disorder
0.73 0.24–2.19 .57 1.65 0.79–3.43 .18 2.17 0.88–5.34 .09 2.55 0.78–8.40 .12 1.44 0.49–4.24 .50
Current depressive disorder only 0.53 0.13–2.18 .38 1.41 0.61–3.23 .42 2.16 0.82–5.71 .12 2.58 0.70–9.46 .15 1.60 0.50–5.10 .42
Current anxiety disorder only 1.02 0.34–3.11 .97 2.70 1.31–5.56 .007 2.87 1.16–7.11 .02 3.47 1.03–11.66 .05 2.69 0.94–7.67 .06
Current depressive and
anxiety disorder
1.37 0.49–3.86 .55 3.54 1.79–6.98 b.001 4.96 2.14–11.49 b.001 4.75 1.46–15.47 .01 2.24 0.79–6.37 .13
a Based on logistic regression analyses adjusted for age, sex, years of education, smoking status, alcohol use, physical activity and BMI; in all analyses the speciﬁc
CVD or CHD subtype was compared to persons without any CVD (N=2651).
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persons with a current depressive disorder (OR=1.77, 95%
CI=0.89–3.54), albeit this was not statistically signiﬁcant.
Odds of CHD for persons having an anxiety disorder in
addition to a depressive disorder were more than twofold
increased compared to having a depressive disorder alone
(OR=2.40, 95%CI=1.27–4.54).
Table 4 shows the results of separate sociodemographic-
adjusted logistic regression analyses examining associations
of depressive and anxiety disorder characteristics with CHD
in the sub-sample of persons with current psychopathology
(N=1770). No speciﬁc subtype of depressive disorder was
associated with CHD. For persons with a current anxiety
disorder associations with CHD were consistent for persons
with generalized anxiety disorder, social phobia, panic
disorder and agoraphobia. Duration of depressive or anxious
complaints was also not associated with CHD. However, the
severity of depressive symptoms (OR per SD increase=1.32,
95%CI=1.05–1.65) and of anxiety symptoms (OR per SD
increase=1.36, 95%CI=1.11–1.66) were signiﬁcantly asso-
ciated with CHD. In fact, it appeared that the results from
Fig. 1 showing a somewhat higher OR in persons with
comorbid depression and anxiety in comparison to the OR in
persons with anxiety disorders alone could be explained byFig. 1. OR (based on logistic regression analyses adjusted for age, sex, and
education) for CHD in persons with a current depressive and/or anxiety
disorder.severity of symptoms. After additional adjustment for
severity of depressive and anxiety symptoms, odds of CHD
for persons with anxiety disorders were equally increased,
irrespective of additional depressive disorder (OR anxiety
only=1.86, 95%CI=0.91–3.79; OR anxiety and depres-
sion=1.95, 95%CI=1.00–3.78). Lastly, psychoactive medica-
tion use did not statistically signiﬁcantly increase odds of
CHD, but a trend was found for use of benzodiazepines and
higher odds of CHD (OR=1.60, 95%CI=0.95–2.71). Benzo-
diazepine use did not affect the before presented results (i.e.
ORs of CHD as presented in Table 3 and Fig. 1 were very
similar after additional adjustment for benzodiazepine use).4. Discussion
This study examined the association between diagnosed
depressive and anxiety disorders and cardiovascular disease
within a large cohort of depressed and/or anxious persons
and healthy controls. The results show that, individually, both
depressive and anxiety disorders are associated with CVD.
However, the increased prevalence of CHD among depressive
persons appeared to be mainly owing to comorbidity of
anxiety disorders. No associations were found with stroke.
Severity of depressive and anxiety symptoms—but no other
clinical factors—identiﬁed those with the highest prevalence
of CHD.
Relatively few studies have examined the link between
anxiety and CHD and most of these studies assessed anxiety
symptoms, but not diagnosis. Although the link between
anxiety (symptoms) and CHD has been more consistently
found in initially CHD-free populations than among heart
patients (Suls and Bunde, 2005), a recent study (Frasure-Smith
and Lesperance, 2008) showed that both a generalized anxiety
disorder, as well as severity of anxiety symptoms were
associated with an increased risk of major adverse cardiac
events in patients with stable coronary artery disease. Our
results demonstrate that within a psychopathology-based
population the prevalence of CHD is increased across a wide
range of diagnosed anxiety disorders (social phobia, general-
ized anxiety disorder, panic disorder and agoraphobia). In fact,
personswho suffered fromany anxiety disorder in thepast year
were about three times as likely to have CHD. Given the
widespread prevalence of anxiety disorders, these results
suggest that the role of anxiety disorders in CHD is important
Table 4
Association of depressive and anxiety disorder characteristics with coronary heart disease.
No CHD N=1673 CHD N=97
% or mean (SD) % or mean (SD) OR 95% CI p
Unadjusted Adjusted a
Type of depressive disorder b
First onset major depressive disorder (vs. recurrent) 46.4 41.8 0.95 0.56–1.61 .85
Atypical symptoms 20.8 24.2 1.53 0.83–2.83 .17
Melancholic symptoms 11.9 16.7 1.08 0.53–2.18 .84
Late onset (≥30 years old) 35.0 61.8 1.11 0.65–1.92 .70
Type of anxiety disorder c
Generalized anxiety disorder 44.9 50.0 1.15 0.72–1.82 .56
Social phobia 55.5 53.6 1.08 0.68–1.72 .74
Panic disorder 55.1 53.6 1.13 0.71–1.80 .62
Agoraphobia 16.0 25.0 1.21 0.70–2.10 .49
Late onset (≥30 years old) 22.6 43.4 1.06 0.65–1.73 .83
Duration d
Percent of time with symptoms in past 4 years 52.4 (35.6) 58.8 (35.3) 1.02 0.56–1.86 .95
Severity d
Current depressive symptoms score (IDS) 28.5 (12.4) 32.2 (13.0) 1.32 e 1.05–1.65 .02
Current anxiety symptoms score (BAI) 16.5 (10.8) 20.0 (9.7) 1.36 e 1.11–1.66 .003
Psychoactive medication d
Selective serotonin reuptake inhibitor use 25.1 21.6 0.87 0.52–1.45 .60
Tricyclic antidepressant use 3.8 7.2 1.56 0.68–3.57 .30
Other antidepressant use 8.8 12.4 1.26 0.65–2.41 .49
Benzodiazepine use 10.5 22.7 1.60 0.95–2.71 .08
a Based on logistic regression analyses adjusted for age, sex, and education; each line represents a single analysis.
b Within sub-sample of persons with a current (past year) depressive disorder: N=1266; ﬁrst onset vs. recurrent: persons with dysthymia only (N=44) were
excluded.
c Within sub-sample of persons with a current (past year) anxiety disorder: N=1352.
d Within sub-sample of persons with a current (past year) depressive and/or anxiety disorder: N=1770.
e Per SD increase: IDS: SD=12.9; BAI: SD=10.7.
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suggest that cardiac symptoms in anxiety persons might really
indicate heart disease and underdiagnosing heart disease in
anxiety patients might be a problem.
The possible overlap in symptoms between anxiety
disorders and heart disease could also pose a problem in
examining the association between these two. We tried to
handle this issue by only including deﬁnite cases of anxiety
and by conﬁrmation of medication use appropriate for CVD.
Evenwhen further excluding personswith symptoms of chest
pain and use of a beta-blocker only—sometimes described to
relieve anxiety symptoms—associations of anxiety disorders
with CHD remained. Moreover, associations between anxiety
disorders and CHD were found across different types of both
CHD and anxiety disorders and were not conﬁned to for
instance angina pectoris and panic disorder, supporting the
conclusion that the strong association observed between
anxiety and CHD is real.
Although a depressive disorder diagnosis was associated
with CVD, this relationship appeared to be largely explained
by comorbid anxiety. Previous research in the general
population and among heart patients consistently showed
an association between depression and CVD. Importantly,
these studies often did not take into account comorbid
anxiety, but many depressed persons have a comorbid
anxiety disorder (in our sample 67%). Similar to our study
within a psychopathology-based population, Strik et al.
(2003) found that anxiety and not depressive symptoms
were an independent predictor of cardiac events among heartpatients and accounted for the relationship between depres-
sive symptoms and cardiac events. Longitudinal studies
should further disentangle the associations between depres-
sion, anxiety and CHD.
Considering clinical characteristics, highest prevalences of
CHD were found among those with the most severe
symptoms of depression and anxiety. This might suggest
that more severe symptoms induce an extra increased risk of
CHD. Otherwise, as symptom scales of depression and anxiety
often include a set of somatic items, it is possible that severity
of depression or anxiety partly reﬂects severity of heart
complaints (Sorensen et al., 2005). Otherwise, somatic health
factors might be more important in depressive disorders that
are associated with CVD. This might also (partly) explain why
other studies, mostly conducted within somewhat older
populations, which generally have more somatic conditions,
do ﬁnd more support of a relationship between depression
and CVD.
Little evidence was found of other clinical characteristics of
depressive or anxiety disorders to be speciﬁcally related to
CHD. Although we had expected longer lasting psychiatric
disorders to be associated with higher prevalence of CVD, the
results did not corroborate this. This ﬁnding somewhat
decreases the plausibility of depressive and anxiety disorders
directly causing CVD. Also, associations with remitted psychi-
atric disorders were not statistically signiﬁcant, perhaps partly
due to decreased reliability of diagnosis assessment in themore
far away past. On a more positive side, this might suggest that
when persons remit from depressive or anxiety disorders, the
247N. Vogelzangs et al. / Journal of Affective Disorders 125 (2010) 241–248odds of CHD decreases. Further, antidepressant medication use
was not associated with CHD. Tricyclic antidepressants have
been well described to have cardiovascular effects (Glassman,
1998), but this might have been counterbalanced in our study
by the fact that these medications are therefore contra-
indicated in heart patients. Benzodiazepine use was somewhat
more prevalent among persons with CHD, but whether they
increase risk of CVD or whether this ﬁnding is a reﬂection of
poorer health status in persons with CVD, cannot be decided
from this study.
Interestingly, our results only show an association with
CHD, but not with stroke. Although some studies do relate
psychopathology to stroke (Everson et al., 1998), this has been
much less examined than CHD. We examined the association
between depression, anxiety and stroke in a relatively young
population where stroke was not very prevalent and we were
not able to distinguish between ischemic or a hemorrhagic
stroke. As an association of depression and anxiety with
speciﬁcally ischemic stroke is expected, hemorrhagic strokes
might have diluted the association.
Our study has some important strengths. We made use of
a large sample of persons with diagnosed psychopathology to
investigate whether true psychiatric diagnoses of both
depression and anxiety are indeed associated with a
heightened prevalence of CVD. Furthermore, we were able
to examine the effects of a large amount of clinical
characteristics of depressive and anxiety disorders. Some
limitations have to be noted as well. Our results are based on
cross-sectional data. This makes it impossible to draw any
conclusions about the causality of associations between
depressive and anxiety disorders and CHD. However, a strong
association between anxiety disorder and CHD existed in
persons with an onset of psychopathology before 30 years.
Since CHD hardly occurs before the age of 30, an early onset
suggests that psychopathology was present before CHD.
Additionally, as depression and anxiety are highly comorbid
and had an early onset in most persons (only 269 of 2315 had
late onset), it is unlikely that the ﬁnding that anxiety is more
strongly than depression associated with CHD was biased by
the cross-sectional design. Another limitation is that the
presence of heart disease was not veriﬁed by general practice
or hospitalization records. However, self-report was con-
ﬁrmed by medication use and previous research has shown
good concordance between self-report of heart disease and
general practitioners information, with especially little over-
reporting (Kehoe et al., 1994;Kriegsman et al., 1996).
In conclusion, our results show that anxiety disorders are
more strongly associated with coronary heart disease than
depressive disorders and might partly account for the widely
reported association between depression and heart disease.
The highest prevalence of CHD is found among those with the
most severe psychiatric symptoms, such as those persons
with comorbid depression and anxiety. Anxiety as possible
risk factor for cardiovascular disease needs to be more
elaborately investigated in future research, and deserves
more attention in clinical care as well.Role of funding source
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